News

The company may be on track to its next product.

Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]

Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.

PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.

August was good to U.S. stock investors. All three major U.S. indexes are on track to finish the month in the green—something that has happened since May. The tech-focused Nasdaq is leading the way, up about 4.

August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]

SCHD just delivered a return most dividend investors spend a decade waiting for, and that success created a problem nobody predicted. Whether fresh money belongs in the fund right now depends on a tradeoff that long-term holders never had to face.

Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...

The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck […]

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: Here’s what I would do: I think that you have to […]

The signs were not in the headline growth rate but in which two products were trading places.

Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.

BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical

BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, met its main goals in a first-ever Phase 3 trial for melanoma. The news sent Moderna shares up as much as 177%, adding $44 billion to its market value, while Merck […]

On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said their personalized melanoma vaccine, intismeran, combined with Merck’s Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported. It is the first positive late-stage […]

BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Investing.com -- BioNTech SE (NASDAQ: BNTX) shares tumbled 10% in Friday, rapidly unwinding the gains the stock had accumulated during a sector-wide mRNA rally just days prior. The selloff was triggered by the company’s announcement that it has terminated a Phase 2 trial for its mRNA cancer vaccine in colorectal cancer due to futility—a stark reality check for investors hoping the mRNA oncology revolution would be a rising tide that lifts all boats. The timing of the setback could not be more vi

Over the past 12 months, the State Street SPDR S&P Biotech ETF is up around 85% versus roughly 20% for the S&P 500. Last week added an exclamation point: Moderna more than doubled in a single session after its mRNA cancer vaccine, developed with Merck, cleared a late-stage melanoma trial. For decades, U.S. and other Western companies enjoyed something close to a monopoly on cutting-edge science.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

Merck stock has delivered strong gains over the past few years, while the latest valuation checks send mixed signals as the Discounted Cash Flow (DCF) intrinsic value estimate suggests upside but traditional market multiples point the other way. The stock also carries a low broader value score, which leans more toward expensive than clear bargain territory. Over 5 years, Merck has returned 126.6%, which sets expectations high for what investors are willing to pay for the next leg of the...

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with surgically removed high-risk melanoma. The result lifted other mRNA developers because it provided the strongest evidence yet that […]

House Speaker Mike Johnson (R-La.) said prescription drug prices have fallen to their lowest level in more than 60 years, crediting President Donald Trump and congressional Republicans for delivering lower costs for Americans. Johnson Touts 60-Year Low In Prescription Drug...

The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.

The company now leads with a cost-savings total and a growth rate that does not begin until the end of the decade, which tells a holder far less about whether its medicines are winning.